{"schema_version":"1.0","type":"article","title":"Pancreatic Cancer Breakthrough: After RAS Inhibitors, PRMT5/MAT2A Combinations Open the Next Layer of Upside","url":"https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination-en.md","lang":"en","date":"2026-06-27","publish_at":"2026-06-27T10:30:00+08:00","updated_at":"2026-06-27","category":"商業分析系列","topic":"商業分析系列","tags":["Pancreatic Cancer","RAS","PRMT5","MAT2A","Synthetic Lethality","Clinical Data","Biotech Investing","BD"],"summary":"Pancreatic cancer is moving into a new phase of precision combination therapy, as RAS inhibition meets MTAP-selective PRMT5 and MAT2A strategies.","key_points":[],"facts":[],"sections":["01｜Why Vopimetostat + Daraxonrasib Matters","02｜Safety Is the Next Gate","03｜IDEAYA Enters the Race: PRMT5 Becomes a Selectivity Battle","04｜MAT2A Is the Third Piece of the Puzzle","05｜Why Large Pharma Will Watch This Field Closely","Conclusion｜Pancreatic Cancer Is Moving Toward Precision Combination Therapy"],"references":[{"title":"[0] Company websites and public disclosures: Revolution Medicines, Tango Therapeutics, and IDEAYA Biosciences.","source":"","date":"","url":""},{"title":"[1] PubMed","source":"Daraxonrasib / RASolute-302-related research:","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/42223072/"},{"title":"[2] Tango Therapeutics","source":"PRMT5 program overview:","date":"","url":"https://www.tangotx.com/programs/prmt5/"},{"title":"[3] Investor's Business Daily","source":"Tango Therapeutics / Revolution Medicines combination data coverage:","date":"","url":"https://www.investors.com/news/technology/tango-therapeutics-tngx-stock-revolution-medicines-rvmd-stock-pancreatic-cancer/"},{"title":"[4] IDEAYA Biosciences","source":"IDE892 initiates a Phase 1/2 clinical combination study in MTAP-deleted pancreatic and lung cancers:","date":"","url":"https://ir.ideayabio.com/2026-06-15-IDEAYA-Biosciences-Announces-IDE892,-a-Potential-Best-in-Class-MTA-Cooperative-PRMT5-Inhibitor,-Initiates-a-Phase-1-2-Clinical-Combination-Study-in-MTAP-Deleted-Pancreatic-and-Lung-Cancers"},{"title":"[5] IDEAYA Biosciences","source":"First patient in for Phase 1 trial of IDE892 and MTAP/CDKN2A pipeline update:","date":"","url":"https://ir.ideayabio.com/2026-03-09-IDEAYA-Biosciences-Announces-First-Patient-In-for-Phase-1-Trial-of-IDE892,-a-Potential-Best-In-Class-PRMT5-Inhibitor-for-MTAP-Deleted-Solid-Tumors,-and-Provides-MTAP-and-CDKN2A-Pipeline-Update"}],"images":[{"alt":"English figure: RAS inhibition plus MTAP-selective PRMT5 targeting in pancreatic cancer","url":"https://drugnews.com.tw/assets/articles/pancreatic-cancer-ras-prmt5-mat2a-combination-en/figure-01.png"},{"alt":"English figure: early efficacy signal versus safety and dose questions","url":"https://drugnews.com.tw/assets/articles/pancreatic-cancer-ras-prmt5-mat2a-combination-en/figure-02.png"},{"alt":"English figure: IDEAYA's PRMT5/MTA and MAT2A strategy","url":"https://drugnews.com.tw/assets/articles/pancreatic-cancer-ras-prmt5-mat2a-combination-en/figure-03.png"},{"alt":"English figure: RAS plus PRMT5 plus MAT2A triplet rationale","url":"https://drugnews.com.tw/assets/articles/pancreatic-cancer-ras-prmt5-mat2a-combination-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/pancreatic-cancer-ras-prmt5-mat2a-combination-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-27）。Pancreatic Cancer Breakthrough: After RAS Inhibitors, PRMT5/MAT2A Combinations Open the Next Layer of Upside。https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}